Minerva Neurosciences Inc (NERV) Stock AnalysisNERVMinerva Neurosciences Inc

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Minerva Neurosciences Inc (NERV) is currently trading at $2.345, which is significantly below its 52-week high of $8.80, indicating potential upside. However, the company has a negative earnings per share (EPS) of -0.14 expected for the next quarter and a recent trend of declining revenues, with a 20-day change of -29.37%. The RSI is at 46.487, suggesting the stock is neither overbought nor oversold. Given the high volatility and recent earnings miss, it may be prudent to hold rather than buy at this time.

3 analysts cover NERV: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.